Lazard Asset Management
VERV

Lazard Asset Management’s Verve Therapeutics VERV Stock Holding History

Lazard Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85
Closed – – 2591
2024
Q4 		$0 Hold
85
– – ﹤0.01% 2553
2024
Q3 		$0 Sell
85
-56
-40% -$325 ﹤0.01% 2465
2024
Q2 		$0 Sell
141
-3,899
-97% -$24.5K ﹤0.01% 2438
2024
Q1 		$52K Sell
4,040
-751
-16% -$9.96K ﹤0.01% 1709
2023
Q4 		$65K Buy
4,791
+2,776
+138% +$34.4K ﹤0.01% 1823
2023
Q3 		$26K Buy
2,015
+89
+5% +$1.43K ﹤0.01% 2059
2023
Q2 		$35K Buy
1,926
+55
+3% +$916 ﹤0.01% 1942
2023
Q1 		$26K Buy
1,871
+396
+27% +$7.75K ﹤0.01% 1992
2022
Q4 		$27K Sell
1,475
-404
-22% -$10.7K ﹤0.01% 2077
2022
Q3 		$64K Buy
+1,879
New +$60K ﹤0.01% 1686

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Lazard Asset Management's VERV Position: Q1 2025 in Review

Lazard Asset Management sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 85 shares.

Lazard Asset Management first reported a position in VERV in Q3 2022 and held it in 10 quarters. The position peaked at $65K in Q4 2023. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Lazard Asset Management reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 85 Verve Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 10 quarters.
  • Lazard Asset Management's Verve Therapeutics position peaked at $65K in Q4 2023.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.